top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video
Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer
Daniel Petrylak, MD, and Nicholas Vogelzang, MD, share insight on the emerging role of chemotherapy in metastatic prostate cancer. View now
Publication Bottom Border
Border Publication
x